Camille Samuels specializes in early-stage biotechnology investing at Versant Ventures. Cami brings 14 years of venture capital and operating experience to her portfolio companies. She enjoys helping talented entrepreneurs build exceptional companies.
Cami joined Versant in early 2000, shortly after its formation. Prior to Versant, she was responsible for business development at Tularik, Inc. (subsequently acquired by Amgen) where she in-licensed two of the company's clinical-stage products and led Tularik’s Technology Acquisition Group. Before Tularik, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine, and was a management consultant to healthcare and biotech companies at LEK Consulting.
Cami currently serves as a board member of the following companies: Achaogen, APT Pharmaceuticals, Kythera Biopharmaceuticals, and Transcept Pharmaceuticals, Inc. (TSPT), a public company. Cami was previously a board member at NovaCardia (acquired by Merck) and ParAllele (acquired by Affymetrix). In addition, she served as a board observer at several companies, including Alexza (public), Fluidigm, Genomic Health (public) and Syrrx (acquired by Takeda).
Cami earned her Bachelor's degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Camille a Henry Crown Fellow.